Assessing CD36 and CD47 expression levels in solid tumor indications to stratify patients for VT1021 treatment

IF 6.8 1区医学 Q1 ONCOLOGY

NPJ Precision Oncology Pub Date : 2024-12-03 DOI:10.1038/s41698-024-00774-9

Suming Wang, Victor Zota, Melanie Y. Vincent, Donna Clossey, Jian Jenny Chen, Michael Cieslewicz, Randolph S. Watnick, James Mahoney, Jing Watnick

引用次数: 0

Abstract

Despite the development of cancer biomarkers and targeted therapies, most cancer patients do not have a specific biomarker directly associated with effective treatment options. We have developed VT1021 that induces the expression of thrombospondin-1 (TSP-1) in myeloid-derived suppressor cells (MDSCs) recruited to the tumor microenvironment (TME). Our studies identified CD36 and CD47 as dual biomarkers that can be used as patient stratifying tools and prognostic biomarkers for VT1021 treatment.

Abstract Image

查看原文本刊更多论文

评估CD36和CD47在实体瘤指征中的表达水平，以对VT1021治疗的患者进行分层。

尽管癌症生物标志物和靶向治疗的发展，大多数癌症患者没有一个特定的生物标志物直接与有效的治疗方案相关。我们已经开发了VT1021，诱导血小板反应蛋白-1 （TSP-1）在募集到肿瘤微环境（TME）的髓源性抑制细胞（MDSCs）中的表达。我们的研究确定CD36和CD47作为双重生物标志物，可作为VT1021治疗的患者分层工具和预后生物标志物。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

NPJ Precision Oncology ONCOLOGY-

CiteScore

9.90

自引率

1.30%

发文量

审稿时长

18 weeks

期刊介绍： Online-only and open access, npj Precision Oncology is an international, peer-reviewed journal dedicated to showcasing cutting-edge scientific research in all facets of precision oncology, spanning from fundamental science to translational applications and clinical medicine.